Beth Israel Deaconess Medical Center nationally recognized by U.S. News & World Report. August 05, 2026 BIDMC named in top three hospitals in Massachusetts. Boston, MA - Beth Israel Deaconess Medical Center (BIDMC) has been recognized for its high-quality care by U.S. News & World Report's 2026-2027 Best Hospitals edition, placing in the top 50 hospitals nationwide in eight specialties. BIDMC was ranked in the top 10 nationwide for two of those specialties: obstetrics & gynecology and diabetes & endocrinology. BIDMC was also named as the #3 best hospital in the Boston Metro Area region and #3 best hospital in Massachusetts. "Being again nationally recognized by U.S. News & World Report reflects the high-quality care teams across BIDMC provide to patients and their families," said Pete Healy, president, BIDMC & divisional president, Metro Boston, Beth Israel Lahey Health. "I am thankful for the commitment of our physicians, nurses, and staff to excellent and compassionate care." The eight specialties that BIDMC received national rankings include: * Obstetrics & Gynecology * Diabetes & Endocrinology * Gastroenterology & GI surgery * Pulmonology & Lung surgery * Cancer Care * Neurology & Neurosurgery * Heart & Vascular * Geriatrics The hospital received 20 high-performing ratings across specialties and procedures & conditions, including aortic valve surgery; colon cancer surgery; ear, nose & throat surgery; gynecological cancer surgery; heart bypass surgery; heart failure; kidney failure; leukemia, lymphoma & myeloma; lung cancer surgery; prostate cancer surgery; stroke; and urology. U.S. News evaluated nearly 4,500 hospitals across 14 adult specialties and 23 procedures and conditions; less than half earned recognition in any of those 37 areas of care. To determine the Best Hospitals, U.S. News analyzed each hospital's performance based on objective measures such as risk-adjusted mortality rates, preventable complications and patient experience. The Best Hospitals Specialty rankings methodology and Procedures & Conditions ratings methodology measure patient outcomes using data from over 800 million records of patient care. About Beth Israel Deaconess Medical Center. Beth Israel Deaconess Medical Center is a leading academic medical center, where extraordinary care is supported by high-quality education and research. BIDMC is a teaching affiliate of Harvard Medical School, and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding. BIDMC is the official hospital of the Boston Red Sox. Beth Israel Deaconess Medical Center is a part of Beth Israel Lahey Health, a healthcare system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, more than 4,700 physicians and 39,000 employees in a shared mission to expand access to great care and advance the science and practice of medicine through groundbreaking research and education. Director of Media Relations Sarah finlaw. Please note: The contact information above is for journalists and news media only. For patient care and all other inquiries, please contact your doctor or BIDMC directly.

Scott rotig, MD, PhD, joins Pathology as new BIDMC Vice Chair of Hematopathology. Scott J. Rodig, MD, PhD is an internationally recognized hematopathologist, physician-scientist, and academic leader has joined the BIDMC Department of Pathology as Vice Chair of Hematopathology, and new position for the department. A Professor of Pathology at Harvard Medical School and an attending pathologist at Brigham and Women's Hospital and Dana-Farber Cancer Institute, Dr. Rodig brings more than two decades of clinical, research, and leadership experience at the forefront of hematologic malignancies. He has authored over 350 peer-reviewed publications, ranks among the top 1% of most-cited researchers in clinical medicine, and has played a pivotal role in discoveries and diagnostic innovations that have shaped modern lymphoma care. In his new role, Dr. Rodig will lead and strengthen collaboration between Dana-Farber's Hematologic Malignancies programs and BIDMC Pathology, advancing integrated clinical care, translational research, and education.

BIDMC wins NIH grant to study ADAMTS13 deficiency beyond rare clotting disorder. June 25, 2026 Beth Israel Deaconess Medical Center (BIDMC) has received a USD 1.63 million NIH R01 grant from the National Heart, Lung, and Blood Institute to investigate ADAMTS13 deficiency across a spectrum of thrombotic disorders - research that carries direct clinical relevance following the FDA approval of recombinant ADAMTS13 (Takeda's Adzynma) for immune thrombotic thrombocytopenic purpura (iTTP). The award funds two parallel lines of inquiry. The first leverages the Harvard TMA Research Collaborative (HTRC), a large single-center iTTP registry assembled by BIDMC investigators, to build predictive models for relapse, refractoriness, and mortality in iTTP patients. The grant also supports the first genome-wide association and admixture mapping studies in iTTP, aimed at identifying germline variants that may explain the disproportionate disease burden observed in certain populations. The second line extends beyond iTTP: using genomic and proteomic data from approximately 800,000 individuals in the UK Biobank and NIH All of Us datasets, the team will examine whether moderate ADAMTS13 deficiency - activity between 10% and 70%, versus the severe deficiency that defines iTTP - contributes to common macrovascular events including stroke, myocardial infarction, peripheral artery disease, and venous thromboembolism. ADAMTS13 cleaves ultra-large von Willebrand factor multimers, preventing pathological platelet aggregation in the microvasculature. In iTTP, severe enzyme deficiency drives diffuse microvascular thrombosis and end-organ damage. The hypothesis that moderate deficiency may also elevate risk for common thrombotic events remains unproven at population scale - making the large multiomic analysis a central scientific contribution of this award. The work could expand the clinical relevance of ADAMTS13 beyond rare thrombotic disease. Recombinant ADAMTS13 is now approved, and if population-scale data indicate that moderate deficiency contributes to stroke or myocardial infarction, the therapeutic and screening implications could extend well beyond the rare iTTP indication. Principal investigator Pavan K. Bendapudi has published on statistical modeling in iTTP and population-scale hemostasis datasets, positioning the group to execute both the registry-based and biobank-scale components of this work. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/